Abbott Laboratories (ABT) — BATS 0/100 — 2026-07-16

Listen to the earnings call audio for free on StockAnalysis

Summary based on Abbott Laboratories earnings call on 2026-07-16

BotFlo AI Transformation Score for $ABT: 0 (0/100)

Sector AI Transformation Score for $ABT: 0 (0/50)

Presentation

(1/7) Q2 results and raised full-year EPS guidance
• 📈 Second quarter sales grew 4.8% with adjusted EPS of $1.31, exceeding the midpoint of guidance and consensus.
• 💰 Abbott reaffirmed full-year comparable sales growth of 6.5% to 7.5% and raised EPS guidance to $5.45 to $5.60.
• 📊 Adjusted gross margin reached 58.0% of sales, up 100 basis points year over year on mix and margin initiatives.

(2/7) Near-term pipeline and upcoming clinical trials
• 🔬 Recent pipeline milestones include completing tectonic coronary IVL pivotal enrollment, FDA submission for Analyte 360 LAA, and CE Mark for Libre Duo dual glucose-ketone sensor.
• 🚀 Management anticipates launching those three products plus TactiFlex Duo PFA in the U.S. in a steady cadence over the next 12 months.
• 🧪 Q4 trial starts are planned for balloon-expandable TAVR, leadless conduction pacing on AVEIR, Cephea mitral replacement, peripheral IVL, and wearable continuous lactate monitoring.

(3/7) Diagnostics demand, core lab, and cancer diagnostics
• 🩺 Diagnostic test volumes from Abbott instruments continue to show strong, stable global demand, with U.S. core laboratory up 7.5%.
• ⚠️ Rapid and Molecular Diagnostics sales declined 8% on a weaker-than-normal respiratory season, while cancer diagnostics grew 13% on mid-teens Cologuard growth.
• 📋 American Cancer Society guidelines reaffirmed Cologuard and Cologuard Plus as preferred colorectal screening options.

(4/7) Nutrition recovery and adult innovation
• 📈 Nutrition sales finished slightly ahead of expectations, rising sequentially by $125 million on improving pediatric and adult trends.
• 🏆 International pediatric nutrition returned to 6.5% growth and U.S. pediatric now reflects full WIC wins, making Abbott market leader in WIC and non-WIC.
• 🥤 Adult nutrition volumes responded to prior price actions, with U.S. Ensure retail consumption up double digits versus last year’s exit and new higher-protein, lower-sugar Ensure versions contributing.

(5/7) EPD emerging-market strength
• 🌍 EPD sales grew 9% with broad-based strength in India, Latin America, and Southeast Asia.
• 📊 Performance is attributed to disciplined execution and rising healthcare demand from access expansion, aging populations, and acute plus chronic treatment needs.
• 💊 A broad portfolio, expanding biosimilars pipeline, and brand equity are said to position EPD for sustainable high single-digit growth.

(6/7) Medical Devices: EP, rhythm, heart failure, and Diabetes Care
• ❤️ Medical Devices sales grew 8.5%, with cardiovascular led by low-teens electrophysiology and high single-digit Rhythm Management and heart failure.
• ⚡ Volt 2.0 PFA launched in the U.S. in May with full market release expected in Q3, while international Volt and TactiFlex Duo drove more than 20% Europe growth.
• 📱 Diabetes Care CGM sales exceeded $2 billion, up 9.5%, with CE Mark for Libre Duo and international rollout planned for the fall pending later U.S. FDA approval.

(7/7) CFO P&L detail and Q3 EPS outlook
• 💱 Foreign exchange added a favorable 0.8% year-over-year to Q2 sales, slightly better than April expectations.
• 📉 Adjusted R&D was 6.9% of sales and adjusted SG&A was 28.6% of sales in the quarter.
• 🎯 Full-year FX is expected to be about +1% on sales, and Q3 adjusted EPS is forecast at $1.38 to $1.46.

Q&A

(1/9) Q&A: U.S. procedure volume health and diagnostic barometer
• 🏥 Ford argues investor fears of decelerating U.S. procedure volumes tied to ACA/Medicaid disenrollment are a flawed assumption for medtech and diagnostics.
• 📊 He notes Medicare, not Medicaid, drives most device procedures and that high-acuity care demand is inelastic.
• 🔬 Abbott’s instrument-sourced U.S. testing volumes remain strong, including in high ACA disenrollment states, with hospital lab business up 13% and U.S. cardio described as better than ever.

(2/9) Q&A: Confidence in second-half sales acceleration drivers
• 📈 Ford says confidence is high because Q2 growth stepped to mid-single digits with monthly acceleration through the quarter.
• 🧩 About 80% of the second-half trajectory lift is expected from nutrition, electrophysiology, core lab, and cancer diagnostics.
• ✅ He cites nutrition ahead of plan, EP launch feedback, easing China VBP drag in core lab, and Cologuard care-gap visibility as supports entering Q3.

(3/9) Q&A: Libre CGM trends, reimbursement, and dual sensor timing
• 📱 Ford remains bullish on CGM, citing 75–80 million potential users versus about 15 million penetrated and calling 8–9% growth a plateau pending reimbursement expansions.
• 💳 He says reimbursement expansion—including possible U.S. type 2 coverage unlocking ~10 million Medicare beneficiaries—can dramatically accelerate growth but is hard to time precisely.
• 🏭 Abbott is in late planning for a fifth ~$1 billion sensor manufacturing facility and will not forecast exact U.S. dual glucose-ketone approval timing despite advanced discussions and positive early European feedback.

(4/9) Q&A: Exact Sciences growth, care gaps, and blood CRC strategy
• 🧬 Cancer diagnostics grew 13% in the first half and Ford is confident in the mid-teens 2026 deal model with a higher second half and smooth integration.
• 📋 Care-gap program volumes typically ramp in the second half as health systems chase HEDIS and Star ratings, and Abbott says it has strong visibility via market access conversations.
• 🩸 On blood-based CRC screening, Ford prioritizes leading overall screening with both best-in-class stool and blood tests rather than blood share alone, using blood to bring unscreened patients into the funnel toward Cologuard.

(5/9) Q&A: Electrophysiology market, Volt/TactiFlex, and share aspirations
• ⚡ Ford declines specific share targets but expects EP to grow faster than market and begin outperforming as Volt moves to full U.S. release and TactiFlex Duo rolls out internationally.
• 🗺️ Physician feedback highlights Volt’s mapping integration, ASC suitability with sedation, and lesion quality, while Europe EP was up 20% in Q2.
• 🔧 Strategy emphasizes selling the full procedure stack—mapping, diagnostics, introducers, ICE—plus pipeline PFA iterations and a potential year-end LAA approval to carry momentum into next year.

(6/9) Q&A: High-level 2027 portfolio growth algorithm
• 🎯 While too early for formal 2027 guidance, Ford reiterates a high-single-digit sales and double-digit EPS target framework, with about 7% still viewed as sustainable.
• 📦 Segment ranges cited are nutrition 2–4%, diagnostics 7–8% with Exact and easing China VBP, EPD 7–9%, and medtech 8–10%, bracketing roughly 6.5–8.5% overall.
• 🔬 Pipeline trials starting in Q4 are expected to contribute in 2029–2030, extending sustainability beyond 2027.

(7/9) Q&A: Structural heart recovery path and pipeline
• ❤️‍🩹 Ford expects structural heart to return to mid- to high-single-digit growth by year-end after U.S. mitral competitive intensity issues, which he says are not price or product problems.
• 👥 Personnel and go-to-market changes are underway; international structural heart grew double digits in the first half with TAVR up 30%.
• 🚀 Longer-term drivers include TriClip Japan, label expansions, Cephea mitral replacement trials, and belief the mitral opportunity can approach TAVR scale.

(8/9) Q&A: Nutrition state of the union and 2–4% algorithm
• 📈 Ford reiterates nutrition is on plan to slightly ahead, with $125 million sequential growth and monthly improvement supporting second-half acceleration and a 2–4% longer-term range.
• 🍼 International pediatric is back to positive growth and highest sales in about two years; U.S. WIC wins are fully baked with restored market leadership, while U.S. Ensure consumption is up double digits versus 2025 exit.
• 🥤 New launches emphasize high protein/low sugar, a collagen protein shake, creatine-containing adult SKU, and a whole-milk infant formula, with possible future guidance upside if momentum continues.

(9/9) Q&A: LAA market appetite and Amulet 360 catalyst
• 🫀 Ford calls LAA an attractive ~$2 billion market where a competitor holds about 90% share, so Abbott’s focus is share capture rather than calling market growth.
• ⭐ Feedback on Amulet 360 is described as fantastic for a more seamless implant, and LAA was moved into the EP business to win concomitant procedures.
• 🚀 Management is excited to relaunch next-generation LAA as a 2027-and-beyond growth driver and sees market-development upside in both EP and interventional concomitant use.